시장보고서
상품코드
1720806

세계의 성장 호르몬 결핍증 시장 보고서(2025년)

Growth Hormone Deficiency Global Market Report 2025

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 175 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

성장 호르몬 결핍증 시장 규모는 앞으로 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.9%로 성장할 것으로 예상되며, 54억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 유전성 질환의 유병률 증가, 전략적 이니셔티브 증가, 연구개발 노력 강화, Gh 질환 이환율 증가, 임상검사수 확대로 인한 것으로 보입니다. 예측 기간의 주요 동향으로는 기술의 진보, 치료 선택의 확대, 진단 기술의 개선, 최근의 동향, 생명 공학의 진보 등을 들 수 있습니다.

유전성 질환의 유병률 증가는 성장 호르몬 결핍증 시장의 확대를 이끌 것으로 예측됩니다. 유전성 질환은 개인의 DNA의 이상이나 돌연변이에 기인하는 병리학이며, 유전성 또는 자연 발생 중 어느 하나입니다. 진단기술의 진보, 인지도의 향상, 임산부 연령의 상승, 돌연변이를 일으키는 환경 요인, 인구 증가, 이환 환자의 생존율의 향상 등, 여러 요인이 만연율의 상승에 기여하고 있습니다. 성장 호르몬 결핍증 치료는 특정 유전 질환과 관련된 성장 관련 합병증을 관리하는 데 도움이 됩니다. 예를 들어 2022년 12월 영국 정부부문인 보건사회의학부(DHSC)가 발표한 보고서에 따르면 2022년 10월에는 약 3만 3,000개의 총 유전체 상당한 서열이 결정되어 평균 진단 수율은 32%로, 특정 질환에서는 61%로 상승했습니다. 그 결과, 유전성 질환의 유병률 증가가 성장 호르몬 결핍증 시장의 성장에 박차를 가하고 있습니다.

성장 호르몬 결핍증 시장의 주요 기업은 소아 성장 호르몬 결핍증(GHD)에 대한 비변형 소마트로핀과 같은 혁신적인 치료의 개척에 주력하고 있습니다. 사용되는 성장 호르몬과 같지만, 스카이트로파로 주 1회 투여할 수 있도록 제제화된 것입니다. Pharma A/S는 소아 GHD의 주 1회 치료로서 SKYTROFA(lonapegsomatropin)를 발매했습니다. 호르몬 연일 투여 요법에 비해 치료 성적이 향상될 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

  • 세계의 성장 호르몬 결핍증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
  • 최종 이용 산업의 분석
  • 세계의 성장 호르몬 결핍증 시장 : 성장률 분석
  • 세계의 성장 호르몬 결핍증 시장 실적 : 규모와 성장, 2019-2024년
  • 세계의 성장 호르몬 결핍증 시장 예측 : 규모와 성장, 2024-2029년, 2034년
  • 세계의 성장 호르몬 결핍증 전체 시장 규모(TAM)

제6장 시장 세분화

  • 세계의 성장 호르몬 결핍증 시장 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
  • 소아 성장 호르몬 결핍증
  • 성인 성장 호르몬 결핍증
  • 세계의 성장 호르몬 결핍증 시장 : 치료별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
  • 약 요법
  • 재조합 인간 성장 호르몬
  • 인간 뇌하수체 추출물
  • 수술
  • 세계의 성장 호르몬 결핍증 시장 : 투여 경로별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
  • 정맥내
  • 근육내
  • 기타
  • 세계의 성장 호르몬 결핍증 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
  • 병원 약국
  • 온라인 약국
  • 소매 약국
  • 세계의 성장 호르몬 결핍증 시장 : 최종사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
  • 병원
  • 재택치료
  • 전문 클리닉
  • 기타
  • 세계의 성장 호르몬 결핍증 시장 : 소아 성장 호르몬 결핍증별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
  • 특발성 성장 호르몬 결핍증
  • 유전적 성장 호르몬 결핍증
  • 성장 호르몬 결핍증 취득
  • 세계의 성장 호르몬 결핍증 시장 : 성인 성장 호르몬 결핍증별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
  • 1차 성장 호르몬 결핍증
  • 2차 성장 호르몬 결핍증

제7장 지역별/국가별 분석

  • 세계의 성장 호르몬 결핍증 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
  • 세계의 성장 호르몬 결핍증 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

  • 성장 호르몬 결핍증 시장 : 경쟁 구도
  • 성장 호르몬 결핍증 시장 : 기업 프로파일
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck KGaA
    • AbbVie Inc.
    • Eli Lilly and Company

제31장 기타 주요 기업 및 혁신 기업

  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Genentech Inc.
  • Ipsen Biopharmaceuticals Inc.
  • Opko Health Inc.
  • JCR Pharmaceuticals Co. Ltd.
  • Ferring Pharmaceuticals Inc.
  • Ascendis Pharma A/S
  • Rani Therapeutics Inc.
  • AnkeBio Co. Ltd.
  • Aeterna Zentaris Inc.
  • Zhongshan Sinobioway Hygene Biomedicine Co. Ltd.
  • Versartis Inc.
  • I-Mab Biopharma Co. Ltd.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

  • 성장 호르몬 결핍증 시장, 2029년 : 새로운 기회를 제공하는 국가
  • 성장 호르몬 결핍증 시장, 2029년 : 새로운 기회를 제공하는 부문
  • 성장 호르몬 결핍증 시장, 2029년 : 성장 전략
    • 시장 동향에 의한 전략
    • 경쟁 전략

제36장 부록

SHW 25.06.02

Growth hormone deficiency (GHD) is a medical condition in which the pituitary gland does not produce enough growth hormone (GH). This deficiency leads to stunted growth and development in children and various metabolic issues in adults. Growth hormone deficiency can be congenital (present at birth) or acquired due to injury, tumors, infections, or other medical conditions affecting the pituitary gland.

The primary types of growth hormone deficiency are pediatric growth hormone deficiency and adult growth hormone deficiency. Pediatric growth hormone deficiency focuses on children with inadequate growth hormone production, resulting in stunted growth and delayed development. Treatments involved are pharmacological therapy, recombinant human growth hormone, human pituitary gland extracts, and surgery. The various routes of administration include intravenous, intramuscular, and others. They are distributed through several channels, such as hospital pharmacy, online pharmacy, and retail pharmacy, and are used by multiple end users, including hospitals, home care, specialty clinics, and others.

The growth hormone deficiency market research report is one of a series of new reports from The Business Research Company that provides growth hormone deficiency market statistics, including the growth hormone deficiency industry global market size, regional shares, competitors with the growth hormone deficiency market share, detailed growth hormone deficiency market segments, market trends, and opportunities, and any further data you may need to thrive in the growth hormone deficiency industry. This growth hormone deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth hormone deficiency market size has grown strongly in recent years. It will grow from $4.06 billion in 2024 to $4.31 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to the rising number of strategic initiatives, increasing incidences of brain tumors, growing demand for hormone therapies, increased elderly population, and rising government funding for healthcare.

The growth hormone deficiency market size is expected to see strong growth in the next few years. It will grow to $5.42 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth during the forecast period can be attributed to the increasing prevalence of genetic disorders, the rising number of strategic initiatives, enhanced research and development efforts, the growing morbidity of Gh disease, and the expanding number of clinical trials. Key trends in the forecast period include technological advancements, the expansion of treatment options, improvements in diagnostic techniques, recent developments, and progress in biotechnology.

The increasing prevalence of genetic disorders is expected to drive the expansion of the growth hormone deficiency market. Genetic disorders are medical conditions resulting from abnormalities or mutations in an individual's DNA, either inherited or occurring spontaneously. Several factors contribute to their rising prevalence, including advancements in diagnostic technology, increased awareness, rising maternal age, environmental factors causing mutations, population growth, and improved survival rates for affected individuals. Growth hormone deficiency treatments help manage growth-related complications associated with certain genetic conditions. For instance, according to a report published in December 2022 by the Department of Health & Social Care (DHSC), a UK-based government department, approximately 33,000 whole genome equivalents were sequenced in October 2022, with an average diagnostic yield of 32%, rising to 61% in specific conditions. As a result, the increasing prevalence of genetic disorders is fueling the growth of the growth hormone deficiency market.

Leading companies in the growth hormone deficiency market are focusing on developing innovative treatments, such as unmodified somatropin, for pediatric growth hormone deficiency (GHD). Unmodified somatropin is the same growth hormone used in daily GHD treatments but formulated for once-weekly administration with Skytrofa. For example, in September 2023, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, launched SKYTROFA (lonapegsomatropin) as a once-weekly treatment for pediatric GHD. This innovation enhances convenience, improves adherence, and offers potentially better treatment outcomes compared to traditional daily growth hormone therapies. As the first and only FDA-approved once-weekly treatment for pediatric GHD, it represents a significant advancement in endocrinology and pediatric care.

In February 2022, Pfizer Inc., a US-based pharmaceutical company, partnered with OPKO Health Inc. to advance the treatment of pediatric growth hormone deficiency (GHD). Through this collaboration, Pfizer and OPKO Health aim to develop and commercialize NGENLA (somatrogon), a next-generation long-acting recombinant human growth hormone that reduces the injection frequency from once daily to once weekly. This approach improves treatment adherence, minimizes the burden of disease management, and enhances the overall quality of life for children and adolescents with GHD. OPKO Health Inc. is a US-based company specializing in the development and commercialization of treatments for growth hormone deficiency.

Major players in the growth hormone deficiency market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Genentech Inc., Ipsen Biopharmaceuticals Inc., Opko Health Inc., JCR Pharmaceuticals Co. Ltd., Ferring Pharmaceuticals Inc., Ascendis Pharma A/S, Rani Therapeutics Inc., AnkeBio Co. Ltd., Aeterna Zentaris Inc., Zhongshan Sinobioway Hygene Biomedicine Co. Ltd., Versartis Inc., I-Mab Biopharma Co. Ltd.

North America was the largest region in the growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in growth hormone deficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the growth hormone deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The growth hormone deficiency market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and specialized services. The market value includes the value of related goods sold by the service provider or included within the service offering. The growth hormone deficiency market consists of sales of recombinant human growth hormones, long-acting growth hormones and combination therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Growth Hormone Deficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on growth hormone deficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for growth hormone deficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The growth hormone deficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Pediatric Growth Hormone Deficiency; Adult Growth Hormone Deficiency
  • 2) By Treatment: Pharmacological Therapy; Recombinant Human Growth Hormone; Human Pituitary Gland Extracts; Surgery
  • 3) By Route Of Administration: Intravenous; Intramuscular; Other Routes Of Administration
  • 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
  • 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
  • Subsegments:
  • 1) By Pediatric Growth Hormone Deficiency: Idiopathic Growth Hormone Deficiency; Genetic Growth Hormone Deficiency; Acquired Growth Hormone Deficiency
  • 2) By Adult Growth Hormone Deficiency: Primary Growth Hormone Deficiency; Secondary Growth Hormone Deficiency
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; AbbVie Inc.; Eli Lilly and Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Growth Hormone Deficiency Market Characteristics

3. Growth Hormone Deficiency Market Trends And Strategies

4. Growth Hormone Deficiency Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Growth Hormone Deficiency Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Growth Hormone Deficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Growth Hormone Deficiency Market Growth Rate Analysis
  • 5.4. Global Growth Hormone Deficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Growth Hormone Deficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Growth Hormone Deficiency Total Addressable Market (TAM)

6. Growth Hormone Deficiency Market Segmentation

  • 6.1. Global Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pediatric Growth Hormone Deficiency
  • Adult Growth Hormone Deficiency
  • 6.2. Global Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pharmacological Therapy
  • Recombinant Human Growth Hormone
  • Human Pituitary Gland Extracts
  • Surgery
  • 6.3. Global Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Intravenous
  • Intramuscular
  • Other Routes Of Administration
  • 6.4. Global Growth Hormone Deficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • 6.5. Global Growth Hormone Deficiency Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End Users
  • 6.6. Global Growth Hormone Deficiency Market, Sub-Segmentation Of Pediatric Growth Hormone Deficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Idiopathic Growth Hormone Deficiency
  • Genetic Growth Hormone Deficiency
  • Acquired Growth Hormone Deficiency
  • 6.7. Global Growth Hormone Deficiency Market, Sub-Segmentation Of Adult Growth Hormone Deficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Primary Growth Hormone Deficiency
  • Secondary Growth Hormone Deficiency

7. Growth Hormone Deficiency Market Regional And Country Analysis

  • 7.1. Global Growth Hormone Deficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Growth Hormone Deficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Growth Hormone Deficiency Market

  • 8.1. Asia-Pacific Growth Hormone Deficiency Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Growth Hormone Deficiency Market

  • 9.1. China Growth Hormone Deficiency Market Overview
  • 9.2. China Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Growth Hormone Deficiency Market

  • 10.1. India Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Growth Hormone Deficiency Market

  • 11.1. Japan Growth Hormone Deficiency Market Overview
  • 11.2. Japan Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Growth Hormone Deficiency Market

  • 12.1. Australia Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Growth Hormone Deficiency Market

  • 13.1. Indonesia Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Growth Hormone Deficiency Market

  • 14.1. South Korea Growth Hormone Deficiency Market Overview
  • 14.2. South Korea Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Growth Hormone Deficiency Market

  • 15.1. Western Europe Growth Hormone Deficiency Market Overview
  • 15.2. Western Europe Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Growth Hormone Deficiency Market

  • 16.1. UK Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Growth Hormone Deficiency Market

  • 17.1. Germany Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Growth Hormone Deficiency Market

  • 18.1. France Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Growth Hormone Deficiency Market

  • 19.1. Italy Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Growth Hormone Deficiency Market

  • 20.1. Spain Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Growth Hormone Deficiency Market

  • 21.1. Eastern Europe Growth Hormone Deficiency Market Overview
  • 21.2. Eastern Europe Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Growth Hormone Deficiency Market

  • 22.1. Russia Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Growth Hormone Deficiency Market

  • 23.1. North America Growth Hormone Deficiency Market Overview
  • 23.2. North America Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Growth Hormone Deficiency Market

  • 24.1. USA Growth Hormone Deficiency Market Overview
  • 24.2. USA Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Growth Hormone Deficiency Market

  • 25.1. Canada Growth Hormone Deficiency Market Overview
  • 25.2. Canada Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Growth Hormone Deficiency Market

  • 26.1. South America Growth Hormone Deficiency Market Overview
  • 26.2. South America Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Growth Hormone Deficiency Market

  • 27.1. Brazil Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Growth Hormone Deficiency Market

  • 28.1. Middle East Growth Hormone Deficiency Market Overview
  • 28.2. Middle East Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Growth Hormone Deficiency Market

  • 29.1. Africa Growth Hormone Deficiency Market Overview
  • 29.2. Africa Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Growth Hormone Deficiency Market Competitive Landscape And Company Profiles

  • 30.1. Growth Hormone Deficiency Market Competitive Landscape
  • 30.2. Growth Hormone Deficiency Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Growth Hormone Deficiency Market Other Major And Innovative Companies

  • 31.1. Novo Nordisk A/S
  • 31.2. Teva Pharmaceutical Industries Ltd.
  • 31.3. Sandoz International GmbH
  • 31.4. Genentech Inc.
  • 31.5. Ipsen Biopharmaceuticals Inc.
  • 31.6. Opko Health Inc.
  • 31.7. JCR Pharmaceuticals Co. Ltd.
  • 31.8. Ferring Pharmaceuticals Inc.
  • 31.9. Ascendis Pharma A/S
  • 31.10. Rani Therapeutics Inc.
  • 31.11. AnkeBio Co. Ltd.
  • 31.12. Aeterna Zentaris Inc.
  • 31.13. Zhongshan Sinobioway Hygene Biomedicine Co. Ltd.
  • 31.14. Versartis Inc.
  • 31.15. I-Mab Biopharma Co. Ltd.

32. Global Growth Hormone Deficiency Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Growth Hormone Deficiency Market

34. Recent Developments In The Growth Hormone Deficiency Market

35. Growth Hormone Deficiency Market High Potential Countries, Segments and Strategies

  • 35.1 Growth Hormone Deficiency Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Growth Hormone Deficiency Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Growth Hormone Deficiency Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제